WealthPLAN Partners LLC Has $1.95 Million Stake in AstraZeneca plc (AZN)

Share on StockTwits

WealthPLAN Partners LLC grew its stake in shares of AstraZeneca plc (NYSE:AZN) by 46.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 55,490 shares of the company’s stock after purchasing an additional 17,709 shares during the quarter. WealthPLAN Partners LLC’s holdings in AstraZeneca were worth $1,949,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in AZN. Jennison Associates LLC bought a new position in shares of AstraZeneca during the second quarter valued at approximately $676,716,000. FMR LLC raised its holdings in shares of AstraZeneca by 35.2% during the second quarter. FMR LLC now owns 20,243,181 shares of the company’s stock valued at $710,738,000 after acquiring an additional 5,272,590 shares in the last quarter. Point72 Asset Management L.P. raised its holdings in shares of AstraZeneca by 214.0% during the first quarter. Point72 Asset Management L.P. now owns 2,905,535 shares of the company’s stock valued at $101,607,000 after acquiring an additional 1,980,335 shares in the last quarter. Crawford Investment Counsel Inc. raised its holdings in shares of AstraZeneca by 168.5% during the first quarter. Crawford Investment Counsel Inc. now owns 1,615,981 shares of the company’s stock valued at $56,511,000 after acquiring an additional 1,014,119 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in shares of AstraZeneca by 293.5% during the second quarter. Sei Investments Co. now owns 1,317,972 shares of the company’s stock valued at $46,274,000 after acquiring an additional 983,055 shares in the last quarter. 15.98% of the stock is owned by hedge funds and other institutional investors.

AZN traded down $0.09 during trading on Wednesday, reaching $37.40. The stock had a trading volume of 40,131 shares, compared to its average volume of 3,982,450. The company has a current ratio of 0.72, a quick ratio of 0.54 and a debt-to-equity ratio of 1.08. The company has a market cap of $94.86 billion, a price-to-earnings ratio of 8.74, a price-to-earnings-growth ratio of 1.99 and a beta of 0.60. AstraZeneca plc has a one year low of $31.99 and a one year high of $39.76.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.38. The business had revenue of $5.16 billion during the quarter, compared to the consensus estimate of $5.09 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The firm’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.87 earnings per share. analysts predict that AstraZeneca plc will post 1.68 EPS for the current year.

The company also recently disclosed a semiannual dividend, which was paid on Monday, September 10th. Shareholders of record on Friday, August 10th were issued a $0.45 dividend. The ex-dividend date was Thursday, August 9th. This represents a yield of 2.35%. AstraZeneca’s dividend payout ratio (DPR) is 20.56%.

AZN has been the subject of a number of recent analyst reports. Jefferies Financial Group downgraded AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. ValuEngine upgraded AstraZeneca from a “hold” rating to a “buy” rating in a report on Saturday, July 28th. BMO Capital Markets reiterated a “buy” rating and issued a $41.00 price objective on shares of AstraZeneca in a report on Friday, May 25th. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, July 16th. Finally, Morningstar reiterated a “hold” rating on shares of AstraZeneca in a report on Tuesday, June 12th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $38.94.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: Growth Stocks

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply